Arrow Medical Limited 02409474 false 2024-07-01 2025-06-30 2025-06-30 The principal activity of the company is that of the design, manufacture and distribution of medical and other related products Digita Accounts Production Advanced 6.30.9574.0 true true true false true 02409474 2024-07-01 2025-06-30 02409474 2025-06-30 02409474 bus:OrdinaryShareClass1 bus:CumulativeShares 2025-06-30 02409474 bus:OrdinaryShareClass2 bus:CumulativeShares 2025-06-30 02409474 bus:Consolidated 2025-06-30 02409474 core:RetainedEarningsAccumulatedLosses 2025-06-30 02409474 core:ShareCapital 2025-06-30 02409474 core:SharePremium 2025-06-30 02409474 core:CurrentFinancialInstruments 2025-06-30 02409474 core:CurrentFinancialInstruments core:WithinOneYear 2025-06-30 02409474 core:Non-currentFinancialInstruments 2025-06-30 02409474 core:Non-currentFinancialInstruments core:AfterOneYear 2025-06-30 02409474 core:CostValuation 2025-06-30 02409474 core:BetweenTwoFiveYears 2025-06-30 02409474 core:WithinOneYear 2025-06-30 02409474 core:FurnitureFittingsToolsEquipment 2025-06-30 02409474 core:LandBuildings 2025-06-30 02409474 core:OtherPropertyPlantEquipment 2025-06-30 02409474 bus:FRS102 2024-07-01 2025-06-30 02409474 bus:Audited 2024-07-01 2025-06-30 02409474 bus:FullAccounts 2024-07-01 2025-06-30 02409474 bus:RegisteredOffice 2024-07-01 2025-06-30 02409474 bus:Director1 2024-07-01 2025-06-30 02409474 bus:Director2 2024-07-01 2025-06-30 02409474 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-07-01 2025-06-30 02409474 bus:OrdinaryShareClass2 bus:CumulativeShares 2024-07-01 2025-06-30 02409474 bus:Consolidated 2024-07-01 2025-06-30 02409474 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 02409474 core:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30 02409474 core:ShareCapital 2024-07-01 2025-06-30 02409474 core:SharePremium 2024-07-01 2025-06-30 02409474 countries:Europe 2024-07-01 2025-06-30 02409474 countries:RestWorldOutsideEurope 2024-07-01 2025-06-30 02409474 countries:UnitedKingdom 2024-07-01 2025-06-30 02409474 core:PlantEquipmentUnderOperatingLeases 2024-07-01 2025-06-30 02409474 core:FurnitureFittings 2024-07-01 2025-06-30 02409474 core:FurnitureFittingsToolsEquipment 2024-07-01 2025-06-30 02409474 core:LandBuildings 2024-07-01 2025-06-30 02409474 core:OtherPropertyPlantEquipment 2024-07-01 2025-06-30 02409474 core:PlantMachinery 2024-07-01 2025-06-30 02409474 core:ParentEntities 2024-07-01 2025-06-30 02409474 core:Subsidiary1 2024-07-01 2025-06-30 02409474 core:Subsidiary1 1 2024-07-01 2025-06-30 02409474 core:UKTax 2024-07-01 2025-06-30 02409474 countries:EnglandWales 2024-07-01 2025-06-30 02409474 2024-06-30 02409474 core:CostValuation 2024-06-30 02409474 core:FurnitureFittingsToolsEquipment 2024-06-30 02409474 core:LandBuildings 2024-06-30 02409474 core:OtherPropertyPlantEquipment 2024-06-30 02409474 2023-07-01 2024-06-30 02409474 2024-06-30 02409474 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-06-30 02409474 bus:OrdinaryShareClass2 bus:CumulativeShares 2024-06-30 02409474 core:CurrentFinancialInstruments 2024-06-30 02409474 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 02409474 core:Non-currentFinancialInstruments 2024-06-30 02409474 core:Non-currentFinancialInstruments core:AfterOneYear 2024-06-30 02409474 core:BetweenTwoFiveYears 2024-06-30 02409474 core:WithinOneYear 2024-06-30 02409474 core:FurnitureFittingsToolsEquipment 2024-06-30 02409474 core:LandBuildings 2024-06-30 02409474 core:OtherPropertyPlantEquipment 2024-06-30 02409474 core:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 02409474 core:ShareCapital 2023-07-01 2024-06-30 02409474 core:SharePremium 2023-07-01 2024-06-30 02409474 countries:Europe 2023-07-01 2024-06-30 02409474 countries:RestWorldOutsideEurope 2023-07-01 2024-06-30 02409474 countries:UnitedKingdom 2023-07-01 2024-06-30 02409474 core:PlantEquipmentUnderOperatingLeases 2023-07-01 2024-06-30 02409474 core:PreviouslyStatedAmount 2023-07-01 2024-06-30 02409474 core:Subsidiary1 1 2023-07-01 2024-06-30 02409474 core:UKTax 2023-07-01 2024-06-30 02409474 2023-06-30 02409474 core:RetainedEarningsAccumulatedLosses 2023-06-30 02409474 core:ShareCapital 2023-06-30 02409474 core:SharePremium 2023-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 02409474

Arrow Medical Limited Annual Report and Financial Statements for the Year Ended 30 June 2025
Brebners Chartered Accountants & Statutory Auditor 1 Suffolk Way Sevenoaks Kent TN13 1YL

Arrow Medical Limited

Contents

Company Information | 1
Strategic Report | 2 to 3
Directors' Report | 4
Statement of Directors' Responsibilities | 5
Independent Auditor's Report | 6 to 8
Statement of Comprehensive Income | 9
Statement of Financial Position | 10
Statement of Changes in Equity | 11
Notes to the Financial Statements | 12 to 22

Arrow Medical Limited

Company Information

Directors | R Hayman W Tarca

Registered office | Hatton Garden Industrial Estate Kington Hereford Herefordshire HR5 3RB

Auditor | Brebners Chartered Accountants & Statutory Auditor 1 Suffolk Way Sevenoaks TN13 1YL

Arrow Medical Limited

Strategic Report for the Year Ended 30 June 2025

The directors present their strategic report for the year ended 30 June 2025.

Principal activity

The principal activity of the company is that of the design, manufacture and distribution of medical and other related products

Fair review of the business

The directors present their Strategic Report for Arrow Medical Limited for the year ended 30 June 2025.
Sales for the year to 30 June 2025 were £1,941,861 (2024 - £2,748,794) and the company sustained a loss in the year of £323,836 (2024 loss of £368,349). The company experienced the loss of a major project discontinued by a customer following third party regulatory supply changes, and a sustained uplift in costs from the prior year driven by inflation, and the continued increases in labour costs.
The focus in this financial year was to continue to stabilise revenue, build new project pipelines and maintain right sizing of operating efficiencies.
The directors acted during the year to reduce its footprint and will be reviewing a strategic review of its focus to further right size and calibrate the business focus to improve its future outlook.

During the last 12 months turnover decreased on the prior year by £806,933, a fall of 29%. Whilst the gross profit percent margin has increased on the prior year, the continued increases in labour costs, with the Company reporting an operating loss of £323,836 against an operating loss for 2024 of £368,349. Other operating income was observed from new project concepts that are expected to be commercialised in the following year.
Future developments
The company will continue its focus on shaping the business towards sustainable profitable revenue streams. Operational right sizing is expected to further increase gross margin, continuing to reduce overheads and aligning the business towards more profitable projects. It will also continue to ensure its operations are as efficient as possible and that it continues to invest in and improve the capability of our infrastructure to give prospective customers a compelling reason to partner and collaborate with Arrow Medical.

Arrow Medical Limited

Strategic Report for the Year Ended 30 June 2025

Principal risks and uncertainties

Price risk
Fluctuations in the price of our inputs are a risk to the Company. The directors constantly review all material inputs on a regular basis to ensure competitive pricing and satisfactory margins for the Company.
Credit risk
The Company operates multiple controls and procedures to manage our credit risk. These controls are regularly reviewed to ensure aged debtors are kept to a minimum.
Inflation
The continued impact of high inflation during the first half of the financial year had an impact on raw material and the supply chain, cost of energy whilst reduced was still double the period of the start of previous year and with an index linking increases in wages driven by two consecutive periods of Minimum Wage increases. The Company continues to carefully assess prices to customers and adjust where necessary to respond to cost rises.
Regulatory risk
The Company does not supply any finished goods under its own brand but continues to enhance its Quality Policies and Management System in support of its customer's needs to meet new regulations, especially under the Medical Device Regulations transition under the EU and UKCA requirements.
Loan notes
Other loans represent subordinated loan notes which are unsecured and-incur no interest. The loans are due to mature by 31 December 2030 unless repaid earlier. If the loans are not repaid they will be written off in full immediately at that point and the Company will have no further liability to the lenders. The loan notes are subordinated to the ordinary creditors of the Company.

Approved by the Board on 22 December 2025 and signed on its behalf by:

.........................................
R Hayman
Director

Arrow Medical Limited

Directors' Report for the Year Ended 30 June 2025

The directors present their report and the financial statements for the year ended 30 June 2025.

Directors of the company

The directors who held office during the year were as follows:

R Hayman

W Tarca

Information included in the Strategic Report

The company has chosen tin accordance with Section 414C(11) Companies Act 2006 to set out the company's strategic report information required by Schedule 7 of the large and medium-sized Companies and Groups (Accounts and Reports) Regulations 2008 to be contained in the directors report. It has done so in respect of financial risk management , exposure and future developments.

Directors' liabilities

The company has purchased Directors' and Officers' liability insurance for Directors and Officers as permitted by Section 233 of the Companies Act 2006.

Disclosure of information to the auditor

Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditors are unaware.

Approved by the director on 22 December 2025 and signed by:

.........................................
R Hayman
Director

Arrow Medical Limited

Statement of Directors' Responsibilities

The directors acknowledge their responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

• | select suitable accounting policies and apply them consistently;

• | make judgements and accounting estimates that are reasonable and prudent;

• | state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

• | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Arrow Medical Limited

Independent Auditor's Report to the Members of Arrow Medical Limited
for the Year Ended 30 June 2025

Opinion

We have audited the financial statements of Arrow Medical Limited (the 'company') for the year ended 30 June 2025, which comprise the Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

• | give a true and fair view of the state of the company's affairs as at 30 June 2025 and of its loss for the year then ended;
• | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
• | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Arrow Medical Limited

Independent Auditor's Report to the Members of Arrow Medical Limited
for the Year Ended 30 June 2025

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• | the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

• | the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

• | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
• | the financial statements are not in agreement with the accounting records and returns; or
• | certain disclosures of directors' remuneration specified by law are not made; or
• | we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities (set out on page 5), the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Arrow Medical Limited

Independent Auditor's Report to the Members of Arrow Medical Limited
for the Year Ended 30 June 2025

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
Based on our understanding of the company and the industry in which it operates, we determined that the principal risks of non-compliance within the highly regulated medical manufacturing industry to be ISO compliance, laws and regulations related to the reporting framework (FRS 102 and the Companies Act 2006) and UK corporate taxation laws and environmental legislation, health and safety legislation. These risks were communicated to our audit team and we remained alert to any indications of non-compliance throughout our audit.
We understood how the company is complying with relevant legislation by making enquiries of management and conducting a review of board minutes. We also considered the results of our audit procedures and to what extent these corroborate this understanding and assessed the susceptibility of the company’s financial statements to material misstatement. This included consideration of how fraud might occur and evaluation of management’s incentives and opportunities for fraudulent manipulation of the financial statements.
We designed our audit procedures to identify any non-compliance with laws and regulations. Such procedures included, but were not limited to, inspection of any regulatory or legal correspondence; challenging assumptions and judgements made by management; identifying and testing journal entries with a focus on large or unusual transactions as determined based on our understanding of the business; and identifying and assessing the effectiveness of controls in place to prevent and detect fraud.
Owing to the inherent limitations of an audit, there remains a risk that a material misstatement may not have been detected, even though we have properly planned and performed our audit in accordance with auditing standards. We are not responsible for preventing non-compliance with laws and regulations and cannot be expected to detect all instances of non-compliance.

The primary responsibility for the detection and prevention of fraud rests with those responsible for governance and management. The further removed non-compliance with laws and regulations is from the events reflected in the financial statements, the less likely the auditor will become aware of it.
The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment, collusion, omission, misrepresentation or forgery.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

......................................
Martin Widdowson (Senior Statutory Auditor)
For and on behalf of
Brebners, Statutory Auditor
1 Suffolk Way
Sevenoaks
TN13 1YL

8 January 2026

Arrow Medical Limited

Statement of Comprehensive Income for the Year Ended 30 June 2025

| Note | 2025 £ | 2024 £
Turnover | 3 | 1,941,861 | 2,748,794
Cost of sales |  | (1,884,835) | (2,623,731)
Gross profit |  | 57,026 | 125,063
Administrative expenses |  | (543,440) | (582,125)
Other operating income | 4 | 184,714 | 134,984
Operating loss | 6 | (301,700) | (322,078)
Other interest receivable and similar income | 7 | 674 | 1,871
Interest payable and similar expenses | 8 | (22,810) | (48,142)
|  | (22,136) | (46,271)
Loss before tax |  | (323,836) | (368,349)
Loss for the financial year |  | (323,836) | (368,349)

The company has no recognised gains or losses for the year other than the results above.

Arrow Medical Limited

Statement of Financial Position as at 30 June 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 13 | 521,757 | 530,007
Investments | 14 | 1 | 1
|  | 521,758 | 530,008
Current assets |  |  |
Stocks | 15 | 268,529 | 646,769
Debtors | 16 | 502,769 | 383,497
Cash at bank and in hand |  | 190,758 | 81,061
|  | 962,056 | 1,111,327
Creditors: Amounts falling due within one year | 18 | (2,321,239) | (2,154,924)
Net current liabilities |  | (1,359,183) | (1,043,597)
Total assets less current liabilities |  | (837,425) | (513,589)
Creditors: Amounts falling due after more than one year | 18 | (123,941) | (123,941)
Net liabilities |  | (961,366) | (637,530)
Capital and reserves |  |  |
Called up share capital |  | 103,750 | 103,750
Share premium reserve |  | 177,250 | 177,250
Retained earnings |  | (1,242,366) | (918,530)
Shareholders' deficit |  | (961,366) | (637,530)

Approved and authorised by the Board on 22 December 2025 and signed on its behalf by:

......................................................................

R Hayman

Director

Company registration number: 02409474

Arrow Medical Limited

Statement of Changes in Equity for the Year Ended 30 June 2025

| Called up share capital £ | Share premium account £ | Profit and loss account £ | Total equity £
At 1 July 2023 | 103,750 | 177,250 | (550,181) | (269,181)
Comprehensive loss for the year
Loss for the year | - | - | (368,349) | (368,349)
Total comprehensive loss for the year | - | - | (368,349) | (368,349)
At 1 July 2024 | 103,750 | 177,250 | (918,530) | (637,530)

Comprehensive loss for the year
Loss for the year | - | - | (323,836) | (323,836)
Total comprehensive loss for the year | - | - | (323,836) | (323,836)
At 30 June 2025 | 103,750 | 177,250 | (1,242,366) | (961,366)

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Hatton Garden Industrial Estate
Kington
Hereford
Herefordshire
HR5 3RB

The principal activity of the company is that of the design, manufacture and distribution of medical and other related products.

2 | Accounting policies

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except any items disclosed in the accounting policies as being shown at fair value and are presented in sterling, which is the functional currency of the entity.

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Summary of disclosure exemptions

The entity satisfied the criteria of being a qualifying entity as defined in FRS102. Its financial statements are consolidated, it the financial statements of Vicplas International Limited. As such, advantage has been taken of the following disclosure exemptions available under paragraph 1.12 of FRS102:
(a) No cash flow statement has been presented for the company.
(b) No disclosure has been made of financial instruments measured at fair value through profit or loss.
(c) No disclosure has been given for the aggregate remuneration of key management personnel.

Group accounts not prepared

Consolidated financial statements are not prepared in accordance with Section 401 Companies Act 2006 as the results of the company and its subsidiary undertakings are included in the consolidated financial statements of Vicplas International Limited..

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

Going concern

The company made a loss for the year ended 30 June 2025 and had net liabilities amounting to £961,366 at that date.
The parent undertaking continues to exhibit its willingness to continue to provide financial support until trading performance improves. At 30 June 2025 the net amount due to the group amounted to £1,731,240 and the parent undertaking has confirmed that the group will not call for repayment until such time that the company has sufficient working capital and on this basis the cashflow forecasts demonstrate that the company has sufficient working capital for a period of at least 12 months from the date of approval of the financial statements.
On the basis of above, and after making enquiries, have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly the directors have continued to adopt the going concern basis in preparing the financial statements.

Judgements and key sources of estimation

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. Key assumptions and other estimation uncertainties provide a risk of causing a material adjustment to the carrying values of assets and liabilities.
Judgements and estimates that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Key sources of estimation uncertainty

(i) Recoverability of debtors
The company establishes a provision for debtors that are estimated not to be recoverable. When assessing recoverability the directors have considered factors such as the ageing of the debtors, past experience of recoverability, and the credit profile of individual or groups of customers.
(ii) Impairment of stocks
At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises turnover on the date products are delivered to customers.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Freehold buildings | 2.5% and 2% straight line
Plant and machinery | 6.67% - 25% straight line
Furniture, fittings and equipment | 10% straight line

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the income statement over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 | Turnover

The analysis of the company's turnover for the year from continuing operations is as follows:

| 2025 £ | 2024 £
Sale of medical equipment | 1,941,861 | 2,748,794

The analysis of the company's turnover for the year by market is as follows:

| 2025 £ | 2024 £
UK | 814,316 | 896,837
Europe | 470,835 | 1,548,407
Rest of world | 656,710 | 303,550
| 1,941,861 | 2,748,794

4 | Other operating income

The analysis of the company's other operating income for the year is as follows:

| 2025 £ | 2024 £
Management charges receivable | 139,503 | 109,200
Other operating income | 45,211 | 25,784

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

5 | Other gains and losses

The analysis of the company's other gains and losses for the year is as follows:

| 2025 £ | 2024 £
Gain/loss on disposal of property, plant and equipment | 800 | -

6 | Operating loss

Arrived at after charging/(crediting)

| 2025 £ | 2024 £
Depreciation expense | 80,789 | 73,327
Foreign exchange losses/(gains) | 19,586 | (18,615)
Payments made under operating leases | 3,681 | 3,692
Profit on disposal of property, plant and equipment | (800) | -

7 | Other interest receivable and similar income

| 2025 £ | 2024 £
Interest income | 674 | 1,871

8 | Interest payable and similar expenses

| 2025 £ | 2024 £
Interest payable on borrowings | 22,810 | 48,142

9 | Staff costs

The aggregate payroll costs (including directors' remuneration) were as follows:

| 2025 £ | 2024 £
Wages and salaries | 1,073,953 | 1,220,087
Social security costs | 108,852 | 111,599
Pension costs | 21,890 | 22,258
| 1,204,695 | 1,353,944

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

The average number of persons employed by the company (including directors) during the year, analysed by category was as follows:

| 2025 No. | 2024 No.
Production | 31 | 30
Management | 5 | 9
Director | 1 | 1
| 37 | 40

10 | Directors' remuneration

The directors' remuneration for the year was as follows:

| 2025 £ | 2024 £
Directors' emoluments | 124,925 | 123,269

11 | Auditor's remuneration

| 2025 £ | 2024 £
Audit of the financial statements | 15,000 | 15,000
Other fees to auditors |  |
Tax compliance services | 2,500 | 2,500

12 | Taxation

Tax charged/(credited) in the income statement

| 2025 £ | 2024 £
Current taxation |  |
UK corporation tax | - | -
Deferred taxation |  |
Total deferred taxation | - | -
Tax expense/(receipt) in the income statement | - | -

The tax on profit before tax for the year is higher than the standard rate of corporation tax in the UK (2024 - higher than the standard rate of corporation tax in the UK) of 19% (2024 - 19%).
The differences are reconciled below:

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

| 2025 £ | 2024 £
Loss before tax | (323,836) | (368,349)
Corporation tax at standard rate | (61,529) | (69,986)
Tax decrease from effect of capital allowances and depreciation | (14,974) | (12,648)
Effect of expense not deductible in determining taxable profit (tax loss) | 19,603 | 23,665
Increase from tax losses for which no deferred tax asset was recognised | 56,900 | 58,969
Total tax charge/(credit) | - | -

13 | Tangible assets

| Freehold land and buildings £ | Furniture, fittings and equipment £ | Plant and machinery £ | Total £
Cost or valuation
At 1 July 2024 | 309,443 | 581,685 | 1,054,325 | 1,945,453
Additions | - | - | 72,539 | 72,539
Disposals | - | - | (51,260) | (51,260)
At 30 June 2025 | 309,443 | 581,685 | 1,075,604 | 1,966,732
Depreciation
At 1 July 2024 | 132,720 | 538,177 | 744,549 | 1,415,446
Charge for the year | 6,538 | 8,989 | 65,262 | 80,789
Eliminated on disposal | - | - | (51,260) | (51,260)
At 30 June 2025 | 139,258 | 547,166 | 758,551 | 1,444,975
Carrying amount
At 30 June 2025 | 170,185 | 34,519 | 317,053 | 521,757
At 30 June 2024 | 176,723 | 43,508 | 309,776 | 530,007

14 | Investments

| 2025 £ | 2024 £
Investments in subsidiaries | 1 | 1

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

Subsidiaries | £
Cost or valuation
At 1 July 2024 | 1
At 30 June 2025 | 1
Carrying amount
At 30 June 2025 | 1
At 30 June 2024 | 1

Details of undertakings

Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking | Registered office | Holding | Proportion of voting rights and shares held
|  |  | 2025 | 2024
Arrow Medical Products Limited | Hatton Garden Industrial Estate, Kington, Herefordshire, HR5 3RB | Ordinary shares | 100% | 100%

15 | Stocks

| 2025 £ | 2024 £
Raw materials and consumables | 191,220 | 415,549
Work in progress | 48,033 | 193,274
Finished goods and goods for resale | 29,276 | 37,946
| 268,529 | 646,769

16 | Debtors

| 2025 £ | 2024 £
Trade debtors | 190,018 | 305,078
Amounts owed by group undertakings | 260,547 | 14,715
Other debtors | - | 8,528
Prepayments | 52,204 | 55,176
| 502,769 | 383,497

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

17 | Cash and cash equivalents

| 2025 £ | 2024 £
Cash on hand | 255 | 255
Cash at bank | 190,503 | 80,806
| 190,758 | 81,061
Bank overdrafts | (355,152) | (238,528)
Cash and cash equivalents | (164,394) | (157,467)

18 | Creditors

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Loans and borrowings | 21 | 355,152 | 238,528
Trade creditors |  | 134,789 | 207,704
Amounts due to group undertakings |  | 1,731,240 | 1,621,771
Social security and other taxes |  | 24,284 | 25,727
Other payables |  | 588 | 13,655
Accruals |  | 75,186 | 47,539
|  | 2,321,239 | 2,154,924
Due after one year |  |  |
Loans and borrowings | 21 | 123,941 | 123,941

Amounts due to group undertakings are unsecured, interest free and repayable on demand.

19 | Pension and other schemes

Defined contribution pension scheme
The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company scheme and amounted to £21,891 (2024: £22,258).

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

20 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary shares of £0.01 each | 1,375,000 | 13,750 | 1,375,000 | 13,750
Deferred shares of £0.09 each | 1,000,001 | 90,000 | 1,000,001 | 90,000
| 2,375,001 | 103,750 | 2,375,001 | 103,750

Ordinary shares have full voting rights, full rights to participate in dividends and distributions and a return of assets on winding up.
Deferred shares carry no voting rights or rights to attend any general meeting or to participate in return of assets in a winding up or reduction of capital. Deferred shares are entitled to participate in dividends at 10p per share subject to the articles.

21 | Loans and borrowings

Non-current loans and borrowings

| 2025 £ | 2024 £
Other borrowings | 123,941 | 123,941

Other borrowings comprises subordinated loan notes which are unsecured and interest free. The subordinated loan notes are repayable in 2030. Repayment is contingent on future profitability.

Current loans and borrowings

| 2025 £ | 2024 £
Bank overdrafts | 355,152 | 238,528

The bank overdraft is secured by a fixed charge over the company's freehold property and a fixed and floating charge over the other assets and undertakings of the company.

Arrow Medical Limited

Notes to the Financial Statements for the Year Ended 30 June 2025

22 | Commitments, guarantees and contingencies

Operating leases

The total of future minimum lease payments is as follows:

| 2025 £ | 2024 £
Not later than one year | 9,225 | 7,717
Later than one year and not later than five years | - | 3,993
| 9,225 | 11,710

Capital commitments
The total amount contracted for but not provided in the financial statements was £Nil (2024: £31,500).

23 | Related party transactions

Summary of transactions with parent

Exemption has been taken under FRS 102 Paragraph 33.1A not to disclose transactions or amounts falling due with companies that are wholly owned within the group.

24 | Relationship between parent and entity

The immediate parent company is Forefront Medical Investment Pte Ltd, a company incorporated in Singapore.
The ultimate parent company is Vicplas International Ltd, a company incorporated in Singapore. The financial statements of Vicplas International Limited are available at 35 Joo Koon Circle, 629110, Singapore.
The smallest and largest group preparing group accounts including the results of the company is headed by Vicplas International Ltd, whose registered office is located at 35 Joo Koon Circle, 629110, Singapore.